2015
DOI: 10.1111/jvim.13637
|View full text |Cite
|
Sign up to set email alerts
|

Dissolution of Urinary Bladder Clots in a Dog with Alteplase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(9 citation statements)
references
References 6 publications
0
6
0
3
Order By: Relevance
“…Die Erkrankung kann ein-oder beidseitig auftreten und zu mikro-oder makroskopischer Hämaturie führen (50,54). Junghunde großer Rassen sind häufiger betroffen (17,54,94). Die IRH ist mitunter schwierig zu diagnostizieren, in der Regel erfolgt die Diagnose zystoskopisch (Abb.…”
Section: Idiopathische Renale Hämaturie (Irh)unclassified
See 2 more Smart Citations
“…Die Erkrankung kann ein-oder beidseitig auftreten und zu mikro-oder makroskopischer Hämaturie führen (50,54). Junghunde großer Rassen sind häufiger betroffen (17,54,94). Die IRH ist mitunter schwierig zu diagnostizieren, in der Regel erfolgt die Diagnose zystoskopisch (Abb.…”
Section: Idiopathische Renale Hämaturie (Irh)unclassified
“…S1) 1 (17,50,54). Obwohl die IRH meist gutartig verläuft, besteht langfristig das Risiko einer Anämie, eines Eisenmangels und einer obstruktiven Uropathie (17,94).…”
Section: Idiopathische Renale Hämaturie (Irh)unclassified
See 1 more Smart Citation
“…Tissue plasminogen activator (tPA) is a serine protease utilized in human and veterinary medicine as a fibrinolytic . Endogenous mammalian tPA, predominantly produced by vascular endothelium, is a critical component in clot dissolution via conversion of plasminogen into plasmin, which breaks down fibrin .…”
Section: Introductionmentioning
confidence: 99%
“…Tissue plasminogen activator (tPA) is a serine protease utilized in human and veterinary medicine as a fibrinolytic. [1][2][3][4][5][6] Endogenous mammalian tPA, predominantly produced by vascular endothelium, is a critical component in clot dissolution via conversion of plasminogen into plasmin, which breaks down fibrin. 7 Recombinant biotechnology has produced several tPA variants, originally intended for intravenous use during acute treatment of myocardial infarction in people.…”
Section: Introductionmentioning
confidence: 99%